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ABSTRACT
Context. Leri–Weill dyschondrosteosis is a clinically variable skeletal dysplasia,
caused by SHOX deletion or mutations, or a deletion of enhancer sequences in the
3’-ﬂankingregion.Recently,a47.5kbrecurrentPAR1deletiondownstreamofSHOX
wasreported,butitsfrequencyandclinicalimportancearestillunknown.
Objective. This study aims to compare the clinical features of diVerent sizes of dele-
tions in the 3’-ﬂanking SHOX region in order to determine the relevance of the
regulatorysequencesinthisregion.
Design. We collected DNA from 28 families with deletions in the 3’-PAR1 region.
Clinicaldatawereavailablefrom23indexpatientsand21relatives.
Results. In 9 families (20 individuals) a large deletion (200–900 kb) was found
and in 19 families (35 individuals) a small deletion was demonstrated, equal to the
recently described 47.5 kb PAR1 deletion. Median height SDS, sitting height/height
ratio SDS and the presence of Madelung deformity in patients with the 47.5 kb dele-
tion were not signiﬁcantly diVerent from patients with larger deletions. The index
patients had a median height SDS which was slightly lower than in their aVected
family members (p D 0:08). No signiﬁcant diVerences were observed between male
andfemalepatients.
Conclusions. The phenotype of patients with deletions in the 3’-PAR1 region
is remarkably variable. Height, sitting height/height ratio and the presence
of Madelung deformity were not signiﬁcantly diVerent between patients
with the 47.5 kb recurrent PAR1 deletion and those with larger deletions,
suggesting that this enhancer plays an important role in SHOX expression.
Subjects Genetics, Medical Genetics, Pediatrics, Statistics
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Leri–Weill dyschondrosteosis (LWD) is caused by haploinsuYciency of SHOX in 60–70%
of cases (intragenic deletions, duplications or mutations), and in 15–31% of patients
withoutanintragenicmutationordeletionaputativeenhancersequenceinthe3’-ﬂanking
region has been demonstrated (Benito-Sanz et al., 2005; Chen et al., 2009). SHOX is
located on the short arm of the X-chromosome in the pseudoautosomal (PAR) 1 region,
thereby escaping X-inactivation, leading to a pseudoautosomal pattern of inheritance
for LWD (Belin et al., 1998; Shears et al., 1998). So far, 7 enhancer sequences, 3 upstream
and 4 downstream of SHOX, have been described (Fukami et al., 2006; Sabherwal et al.,
2007; Durand et al., 2010; Kenyon et al., 2011; Benito-Sanz et al., 2012a; Benito-Sanz et
al., 2012b). Deletion of one or more of the downstream enhancer sequences results in
SHOX haploinsuYciency and LWD. Benito-Sanz et al. (2005) as well as Chen et al. (2009)
describedacohortofpatientswithdiVerentdeletionsinthedownstreamenhancerregion,
where various deletion sizes all resulted in LWD or idiopathic short stature. A deletion
in the enhancer region upstream of SHOX has only recently been reported in one female
patient and her father with idiopathic short stature (Benito-Sanz et al., 2012a), where two
ofthethreeupstreamenhancersequencesweredeleted.
LWD caused by a heterozygous mutation or deletion of SHOX is characterized by short
stature, mesomelia, and Madelung deformity. Penetrance of the phenotype appears to be
incomplete within families (Rappold et al., 2007; Binder, 2011) and Madelung deformity
and short stature tend to be more common and severe in females than in males (Binder,
2011). Mean height of index cases has been reported as  2.2 SDS (Binder, 2011; Rosilio
et al., 2012) and height of aVected mothers and fathers as  2.1 SDS and  1.6 SDS,
respectively(Rosilioetal.,2012).
There is limited information about the phenotype of patients with a deletion in the en-
hancer region downstream of SHOX. However, from the available reports the phenotypic
characteristics do not seem to diVer much from those of patients with SHOX deletions or
mutations(Benito-Sanzetal.,2005;Salmon-Musialetal.,2011;Rosilioetal.,2012).
Recently, a relatively small deletion of PAR1 was found by Caliebe et al. (2012) in a
father and son, of whom the son had short stature ( 2.0 SDS), while the father did not
( 0.44 SDS). Comparable deletions were already demonstrated by Chen et al. (2009), but
their exact size was not determined in detail. Subsequently this deletion was described in
30 unrelated families with LWD or ISS by Benito-Sanz et al. (2012b) equivalent to 15.3%
of probands with LWD and 1.9% of probands with idiopathic short stature, uncovering
a novel downstream enhancer. The clinical phenotype of these patients showed a wide
variabilitywithheightSDSrangingfrom 0.14to 4.68.
We aimed at investigating the frequency of the various deletions in the 3’-ﬂanking
SHOX regionandthepossiblephenotypicdiVerencesbetweenpatientswithdiVerentsizes
ofdeletionsinthisregion.
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Clinical characteristics
In 49 DNA samples sent to the Laboratory for Diagnostic Genome Analysis of the
Department of Clinical Genetics (Leiden University Medical Center, Leiden) and in
six of the DNA samples sent to the Section Genome Diagnostics of the Department of
Genetics (University Medical Center Groningen, Groningen), for the determination of
SHOX defects between 2005 and 2011, we found a deletion in the downstream enhancer
region of SHOX in 29 probands, and 26 of their relatives (total of 28 families). In the
same period in the Laboratory for Diagnostic Genome Analysis of the Department of
Clinical Genetics (Leiden University Medical Center, Leiden) we detected 43 deletions
of the complete gene, 22 mutations (missense, nonsense, splice site or frameshift) and 5
duplicationsofSHOX inatotalof1045patients.
With consent of the Medical Ethical Committee of the LUMC, clinical data were
collected and anonymized for 44 of the 55 patients (23 index patients and 21 aVected
relatives from 23 families). Two of the remaining 11 patients were excluded from the
analysisofclinicalfeatures,becausetheysuVeredfromanadditionaldisorder,whichwould
probably inﬂuence their growth (a skeletal dysplasia of unknown type (inconsistent with
LWD), and a deletion 22q11, respectively). For 9 patients no additional clinical data could
beobtained.
Demographic and clinical data collected were sex, age, height standard deviation score
(SDS), sitting height to height ratio SDS and presence of Madelung deformity. Height
SDSandsittingheight/heightSDSwerecalculatedbasedonDutchnation-widereferences
(Fredriksetal.,2005).WechosenottocollectalldataneededtocalculatetheRappoldscore
(Rappold et al., 2007), because of the limitations of this scoring system in clinical practice:
arm span, and length and bowing of the forearm are seldom measured by clinicians,
appearance of muscular build is not very often spontaneously mentioned in clinical
records, and the use of body mass index gives a higher score for obese patients. Instead,
we chose to collect data about the classical clinical triad of Leri–Weill dyschondrosteosis:
height,sittingheighttoheightratio(SH/H)andpresenceofMadelungdeformity.
Molecular analysis
DNA isolation from peripheral blood and sequence analysis of the SHOX coding region
including intron–exon boundaries was performed using standard procedures (primer
sequences available upon request). Deletions and duplications were detected using the
MRC-HollandMLPAkit(SalsaP018-D1)accordingtothemanufacturer’sinstructions.
Statistical analysis
The t-test and Fisher exact test were used to test for an association of genotype (deletion
including PAR1 probes L05099-L05101 or larger deletions) with height SDS, SH/H SDS,
and the presence of a Madelung deformity. DiVerences between index patients and their
relativesweredetermined,aswellastheinﬂuenceofthegenderofthepatient.
Kant et al. (2013), PeerJ, DOI 10.7717/peerj.35 3/9Figure 1 Schematic representation of the SHOX locus and the surrounding enhancer re-
gions. Schematic representation of the SHOX locus and location of the 3’-ﬂanking PAR1 probes of the
P018-D1 MLPA kit (MRC Holland). Extent of the deletions (blue bars) and the number of families (n) is
indicated with the number of aVected individuals between brackets. The SHOX gene is indicated with a
purple box. The PAR1 probes are indicated with an * and the four downstream enhancers (ECN4, ECN5,
ECR1/CNE7andCNE9)areindicatedwithgreenorred(theenhancerwithinthe47.5deletion)triangles.
The deletion described by Sabherwal includes PAR1 probes L05096-l L05101.
RESULTS
Of the 28 families, 19 had the recurrent 47543 bp (47.5 kb) deletion encompassing
PAR1 probes L05099-L05101 described by Benito-Sanz et al. (2012b), containing a SHOX
enhancersequence(ECR1/CNE7).Thedeletionwasfoundin19indexcasesand16oftheir
relatives. Nine families (10 index patients and 10 relatives) had a larger deletion varying
from a deletion that includes PAR1 probes L05096-L05104 to a deletion including PAR1
probesL05098-L05103(Fig.1).
In the 44 individuals (23 families) of whom clinical information was available, mean
heightSDSwas 1.9(range 4.0to1.2)andSH/HSDS1.5(range 1.6to3.0).Madelung
deformity was present in 19 of 33 patients. Mean height SDS and SH/H SDS in patients
with the 47.5 kb deletions .n D 25/ compared to patients with larger deletions .n D 19/
are shown in Fig. 2. Patients with the 47.5 kb deletion were on average 0.5 SD shorter
than patients with larger deletions, but the diVerence did not reach statistical signiﬁcance
.p D 0:20/. A comparison of the same clinical characteristics between the index patients
and their aVected relatives, and between male and female patients, is also shown in
Fig. 2. No signiﬁcant diVerences were observed in the diVerent subgroups of patients, as
illustrated in Figs. 2 and 3. Presence or absence of a Madelung deformity in the subgroups
of patients mentioned above is summarized in Table 1. No signiﬁcant diVerences were
observedinanyofthesubgroups.
DISCUSSION
We show that the recently reported recurrent 47543 bp (47.5 kb) deletion (Benito-Sanz
et al., 2012b) could also be demonstrated in 19 out of 28 Dutch families (68%) with
a downstream deletion and has a similar clinical phenotype as larger deletions in the
Kant et al. (2013), PeerJ, DOI 10.7717/peerj.35 4/9Figure 2 Height (SDS) range in diVerent subgroups of patients. Height (SDS) range in diVerent
subgroups of patients with a deletion in the downstream enhancer region of SHOX. del 47.5 kb D
deletion that includes PAR1 probes L05099-L05101 in the downstream enhancer of SHOX; other del D
larger deletion in the downstream enhancer of SHOX;  D mean value; n D number of tested individuals;
p D p-value measured by t-test.
downstream region of SHOX. Height SDS, SH/H SDS and the presence of Madelung
deformity all showed a large variation, regardless of deletion size, gender of the patient or
whetherthepatientwasanindexpatientorrelative.
We have now shown that these deletions comprise an important part of our patient
cohort. The lack of previous reports on this deletion could be due to doubt about the
pathogenityofthedeletion,becauseitisnotoverlappingtheformerlydescribedcriticalre-
gionintheenhancerregion(Benito-Sanzetal.,2005).However,recentlythesameresearch
group convincingly reported this deletion to include a previously uncharacterized SHOX
enhancer(ECR1/CNE7),provingthedeletiontobepathogenic(Benito-Sanzetal.,2012b).
The average height SDS in our index cases ( 2.2 SDS) is similar to mean height SDS in
cohorts of patients with SHOX deletions and mutations (Binder, 2011). In the ﬁrst report
on patients with a deletion in the enhancer region Benito-Sanz et al. (2005) demonstrated
12 families with short stature and/or Madelung deformity with variable severity, with
a height SDS ranging from  4.6 SD to 0.85 SD. Rosilio et al. (2012) recently reported a
mean height in their patients with a deletion encompassing SHOX of  2.3 SDS, while in
the same study a mean height of  2.2 SDS was seen in patients with any deletion in the
downstream region. In a smaller sample of patients with a deletion downstream of SHOX
in the study of Salmon-Musial et al. (2011) a mean height SDS of  1.4 SDS was demon-
strated. The results of these reports are in accordance with our observations, although
Kant et al. (2013), PeerJ, DOI 10.7717/peerj.35 5/9Figure3 Sittingheighttoheightratio(SDS)rangeindiVerentsubgroupsofpatients. Sitting height to
height ratio (SDS) range in diVerent subgroups of patients with a deletion in the downstream enhancer
region of SHOX. del 47.5 kb D deletion that includes PAR1 probes L05099-L05101 in the downstream
enhancer of SHOX; other del D larger deletion in the downstream enhancer of SHOX;  D mean value;
n D number of tested individuals; p D p-value measured by t-test.
Table 1 Madelung deformity in diVerent subgroups of patients with a deletion in the downstream
enhancerregionofSHOX. Three comparisons are made in subgroups of patients. del 47.5 kb D deletion
that includes PAR1 probes L05099-L05101 in the downstream enhancer of SHOX; other del D larger
deletion in the downstream enhancer of SHOX.
Madelung
present
Madelung
absent
p-value
(Fisherexacttest)
Patients with del 47.5 kb .n D 17/ 11 6 0.49
Patients with other del .n D 16/ 8 8
Index patients .n D 19/ 10 9 0.72
Relatives .n D 14/ 9 5
Male patients .n D 12/ 7 5 0.72
Female patients .n D 21/ 14 7
in the two last mentioned reports it is suggested that the phenotype in patients with a
deletion in the downstream enhancer region seems to be milder than in patients with a
SHOX mutationordeletion.ThesixpatientsdescribedbySalmon-Musialetal.(2011)with
anomalies downstream of SHOX had a less severe short stature (height SDS  1.4) than
those with other gene anomalies (height SDS  2.5; n D 16). Due to the small size of their
sample they were not able to draw ﬁrm conclusions. Rosilio et al. (2012) reported a higher
percentage of idiopathic short stature (instead of LWD) in patients with a deletion in
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or deletion, suggesting a milder phenotype in patients with a downstream deletion.
However, classiﬁcation of patient groups in this study shows some shortcomings, as also
acknowledged by the authors, and comparisons must be taken with caution. Furthermore
in contrast to the ﬁndings of Rosilio et al. (2012); Chen et al. (2009) reported a higher
percentageofdownstreamdeletionsinLWDpatientscomparedtopatientswithidiopathic
shortstature.Therefore,genotype–phenotypecorrelationsdonotseemobvious.
Comparing all index patients with their relatives shows that mean height SDS is
slightly higher in relatives, although not signiﬁcantly diVerent .p D 0:08/, probably due
to referral bias. DiVerences between male and female patients were not observed in our
study, contrary to what is known about patients with SHOX deletions or mutations where
femalestendtopresentwithamoreseverephenotypethanmales(Binder,2011).However,
furtherconﬁrmationisneededonalargerpatientcohort.
The large variability of the phenotype conﬁrms the ﬁndings in previous reports on
patients with a deletion in the enhancer region 3’ of SHOX (Benito-Sanz et al., 2005; Chen
et al., 2009; Kant et al., 2011; Salmon-Musial et al., 2011; Rosilio et al., 2012). Not all index
patients had short stature, which was also noticed in the study by Salmon-Musial et al.
(2011),andhasbeenobservedinpreviousstudies(Binderetal.,2004;Rappoldetal.,2007).
Looking in detail at this group of eight patients with a height at last examination above
 2 SDS, reason for a diagnostic SHOX analysis was the presence of Madelung deformity
in ﬁve of them, and disproportion in combination with familial disproportionate short
stature in one patient. Another patient had a recent height measurement of  1.4 SDS, but
former height measurements were always around  2 SD, while several family members
had disproportionate short stature. The last patient had a height in the normal range,
but below her target height range. So, short stature is not always the leading clinical sign
to request SHOX analysis, and referring clinicians do take into account other clinical
characteristicsof thepatientandtheir relatives.Thevariability oftheclinical phenotypeis
not limited to deletions of the enhancer region. Also for LWD caused by SHOX mutations
or deletions, the phenotype has been described as highly variable (Binder, 2011). Thus,
penetranceofthephenotypeappearstobeincomplete,evenwithinfamilies.
In conclusion, the phenotype in patients with a deletion in the downstream enhancer
region of SHOX seems comparable to that of patients with a SHOX mutation or deletion,
and the variability of the phenotype in the whole group of patients with a deletion in the
enhancerregionisremarkable.Therecurrent47.5kbdeletiondownstreamofSHOX leads
toaphenotypecomparabletothatoflargerdeletionsinthesameregion.Ourdatasupport
that the 47.5 kb deletion is a pathogenic deletion, and therefore it seems plausible that an
importantenhancerregionislocatedwithinthedeletioninterval.
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